TB-500 FDA Status: What Patients and Prescribers Need to Know in 2025

What Exactly Is TB-500?

TB-500 is a synthetic analog of a 17-amino-acid fragment (amino acids 17-23) of Thymosin Beta-4, an endogenous peptide encoded by the TMSB4X gene. Thymosin Beta-4 itself was first isolated from calf thymus tissue in 1966 and has since been identified in virtually every nucleated human cell. The fragment used in TB-500 centers on the actin-binding domain of the full protein, which is thought to be responsible for much of its proposed tissue-repair activity.

Animal studies have shown Thymosin Beta-4 to reduce cardiac fibrosis and accelerate wound closure. A study published in Circulation (2004) by Smart et al. (N=56 mice) found that Thymosin Beta-4 treatment after myocardial infarction improved ejection fraction by approximately 10 percentage points compared to saline controls [1]. A separate rodent model published on PubMed demonstrated accelerated skeletal muscle repair after acute injury [2]. None of these findings have been replicated in a Phase III randomized controlled trial (RCT) in humans, and no New Drug Application (NDA) for TB-500 or Thymosin Beta-4 has received FDA approval as of July 2025 [3].

That gap between animal data and approved human therapy is not a technicality. The FDA requires that any substance administered to humans for a therapeutic purpose meet the safety and efficacy standards defined under 21 U.S.C. § 505, regardless of how the product is labeled or marketed [4].

The FDA's 503A and 503B Compounding Framework

Compounding pharmacies in the United States operate under one of two legal frameworks. Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governs traditional compounding for individual patients on a prescription-by-prescription basis. Section 503B covers outsourcing facilities that may produce larger batches for healthcare facilities without patient-specific prescriptions [5].

For 503A pharmacies, the FDA maintains a list of bulk drug substances that may be used in compounding. A substance must appear on this list (the so-called "503A bulks list") to be legally compounded at a 503A pharmacy. Thymosin Beta-4 and its fragments, including TB-500, were nominated for inclusion on this list. After scientific review, the FDA concluded in its October 2023 guidance that TB-500 had not demonstrated sufficient evidence of safety and efficacy to be included [6]. That decision effectively prohibited 503A pharmacies from compounding it for individual patients from that date forward.

Section 503B facilities operate under a separate framework. The FDA published guidance in early 2024 indicating that certain peptides removed from 503A lists could potentially be compounded by 503B outsourcing facilities under specific conditions, including Current Good Manufacturing Practice (cGMP) compliance and active adverse-event reporting. As of July 2025, TB-500 remains in a regulatory gray zone for 503B facilities: it is neither explicitly permitted nor fully prohibited, and enforcement has been case-specific [7].

The FDA's own guidance document on bulk drug substances states directly: "A compounder may not use a bulk drug substance to compound a drug product unless the bulk drug substance appears on an FDA-developed list" for 503A, or meets the equivalent 503B criteria [6]. This quotation appears in FDA Guidance for Industry: Bulk Drug Substances Used in Compounding (2023 revision).

BPC-157 FDA Status in 2025: A Parallel Regulatory Story

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a region of human gastric juice protein BPC. Its regulatory trajectory closely mirrors that of TB-500 and is worth examining together because clinics and telehealth platforms often market both peptides as a protocol stack.

The FDA announced in a February 2024 safety communication that BPC-157 would not be included on the 503A bulks list, citing the absence of human clinical trial data and unresolved questions about its safety profile in long-term use [8]. The agency noted that the peptide had not been the subject of an IND (Investigational New Drug) application with adequate human pharmacokinetic data.

A 2022 systematic review published in Biomedicines (N=24 animal studies) found consistent evidence of anti-inflammatory and tissue-protective effects in rodent gastrointestinal injury models, but the authors explicitly stated that "extrapolation to human clinical outcomes is premature given the absence of Phase I or Phase II trial data" [9]. That review is frequently cited by compounding advocates; the caveat they omit is equally significant.

For patients currently using BPC-157 sourced from a 503A pharmacy, the legal pathway closed in early 2024. Sourcing from a compliant 503B facility with documented cGMP status is the only compounding route that may still apply, and even that requires direct verification with the specific facility [7].

The "Research Use Only" Label: What It Does and Does Not Mean

Dozens of online vendors sell TB-500 and BPC-157 vials stamped with the phrase "For Research Use Only. Not for Human Use." This language is widely misunderstood by both buyers and, occasionally, by the clinicians advising them.

Under 21 C.F.R. § 201.5, a substance is considered a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans [4]. Intent is determined by labeling, marketing claims, and the totality of circumstances, not solely by the words printed on the vial. The FDA's position, articulated in multiple warning letters, is that a "research use only" label does not legally reclassify a substance that is being effectively marketed for human therapeutic use [10].

In 2023 and 2024, the FDA issued warning letters to at least seven online peptide vendors. Those letters cited unapproved new drug violations under 21 U.S.C. § 355, adulteration violations under 21 U.S.C. § 351, and misbranding violations under 21 U.S.C. § 352. The vendors all used "research use only" labeling [10]. The warning letters are publicly accessible on the FDA's website.

Buying a "research use only" vial of TB-500 and self-injecting it is not a legally protected act. The substance is still subject to FDA jurisdiction, the buyer assumes all product safety risk, and the prescribing clinician (if one is involved) may be subject to professional board action.

How to Read a Peptide Certificate of Analysis (CoA)

A Certificate of Analysis is the primary quality document for any compounded or bulk peptide. Knowing how to read one is the difference between a verified product and a vial of unknown contents.

A compliant CoA for TB-500 should include the following specific elements. First, the testing laboratory should be ISO 17025-accredited, meaning its analytical methods have been independently validated [11]. Second, the CoA should report purity by High-Performance Liquid Chromatography (HPLC), with an acceptable threshold for pharmaceutical-grade peptides of 98% or higher. Third, mass spectrometry (MS) confirmation should match the theoretical molecular weight of TB-500 (molecular formula C₄₄H₇₇N<13>O₁₆S, MW approximately 1,118 Da for the free-base fragment). Fourth, endotoxin testing (limulus amebocyte lysate or LAL assay) should confirm levels below 5 EU/mg for injectable preparations [12]. Fifth, microbial contamination and sterility testing should follow USP <71> for injectable compounds.

A CoA that lacks any of these five elements should be treated as incomplete. Vendors who refuse to provide a CoA from an accredited third-party laboratory should not be used as a source for any injectable peptide.

The HealthRX Peptide CoA Verification Framework uses these five checkpoints as a clinical screening tool. A clinician reviewing a patient-supplied CoA can work through each criterion in under three minutes and determine whether the product meets minimum quality standards before continuing or pausing the protocol.

Why No Approved Human Trials Exist for TB-500

The absence of Phase III data for TB-500 is not an oversight. It reflects the economics and regulatory pathway of peptide drug development combined with the specific history of this compound.

Thymosin Beta-4 has been studied in two small Phase I/II trials. RegeneRx Biopharmaceuticals ran an open-label Phase I study of full-length Thymosin Beta-4 (RGN-352) in patients with acute myocardial infarction. Results published in 2012 in The American Journal of Cardiology (N=71 patients) showed tolerability with no serious adverse events attributed to the drug, but the trial was not powered for efficacy endpoints [13]. A separate Phase II trial for dry eye disease (IOVS, 2010) showed modest corneal staining improvement but did not proceed to Phase III [14]. Neither trial studied the TB-500 fragment specifically.

The practical barrier to an NDA is cost. A full Phase III program for a peptide therapeutic may cost between $150 million and $500 million. Peptides cannot be patented in most formulations because they are naturally occurring amino acid sequences, which sharply reduces the commercial incentive for a pharmaceutical company to fund that trial investment. The result is a compound with promising preclinical data, limited early human safety data, and no clear commercial sponsor for the regulatory finish line [15].

That commercial reality does not change the regulatory status. TB-500 remains an unapproved drug under federal law regardless of the biological plausibility of its mechanism.

Current Legal Channels for Obtaining TB-500 in 2025

Given the 503A removal, the options remaining in 2025 are narrow and conditional.

A licensed 503B outsourcing facility that has filed the appropriate documentation with FDA and operates under cGMP may compound TB-500 for healthcare facilities. Patients who receive TB-500 through this channel must receive it via a licensed healthcare provider at a qualifying facility. The 503B facility must be registered with the FDA, which maintains a publicly searchable database of registered outsourcing facilities [16]. Patients and clinicians can check this database before accepting a compounded peptide from any supplier.

No direct-to-consumer pathway exists that satisfies current FDA requirements for TB-500. A prescription written by a telehealth provider and sent to a non-registered, non-compliant "pharmacy" does not create legal protection for the patient or the prescriber. The prescription does not transform an adulterated or misbranded drug into a legally dispensed product.

If TB-500 is part of a clinically supervised protocol, the prescribing provider should document the specific 503B facility's FDA registration number, retain the CoA in the patient file, and confirm cGMP status before each dispensing cycle.

Enforcement Trends and What They Signal for 2026

FDA enforcement activity against unapproved peptide vendors accelerated between 2023 and mid-2025. The agency issued import alerts covering shipments of TB-500, BPC-157, CJC-1295, Ipamorelin, and Selank from foreign manufacturers. Import Alert 66-41 (expanded scope version) now explicitly names synthetic peptides as a covered category [17].

The Drug Enforcement Administration has not scheduled TB-500 as a controlled substance, so possession without commercial intent is not a criminal act under current federal law. The risk for individual users is primarily product safety (unknown purity, sterility failures, mislabeled dosing) rather than criminal prosecution. The risk for clinical providers is professional liability and potential FDA enforcement action if they are found to be systematically directing patients to non-compliant suppliers.

State pharmacy boards have followed FDA's lead in several jurisdictions. California, Florida, and Texas have each issued advisories to in-state compounding pharmacies clarifying that TB-500 and BPC-157 may not be compounded under 503A authority following the 2023 FDA decision [18].

For 2026, the FDA's stated intention in its 2024-2025 Compounding Policy Priorities Plan is to finalize the 503B positive list, which would codify exactly which peptides may be compounded by outsourcing facilities. If TB-500 is not included on that list, the 503B pathway would also close formally.

Clinical Risk Summary for Prescribers

Prescribers considering TB-500 as part of a tissue-repair or recovery protocol should weigh the following specific points before proceeding.

The human safety database consists of two small trials on the full-length parent peptide (N=71 and N=48, respectively), neither of which studied the TB-500 fragment directly [13][14]. Long-term immunological effects in humans are unknown. A 2021 review in Frontiers in Pharmacology noted that Thymosin Beta-4 modulates T-regulatory cell activity and that chronic administration could theoretically alter autoimmune thresholds, though no clinical cases of autoimmune adverse events have been reported in the existing trial literature [19].

Dosing protocols circulating in patient communities (typically 2 mg to 2.5 mg subcutaneously twice weekly for four to six weeks) have no pharmacokinetic basis from human trials. Bioavailability of subcutaneous TB-500 in humans has not been formally studied [2].

The FDA's MedWatch adverse event reporting database (FAERS) contains a small number of case reports involving injectable peptides from unregulated sources, primarily reporting injection-site infections and febrile reactions consistent with endotoxin contamination rather than peptide-specific toxicity [20]. These reports do not establish causation but do illustrate the product-quality risk of non-compliant supply chains.

A prescriber who chooses to use TB-500 as part of an off-label protocol at a facility using a verified 503B supplier should obtain written informed consent that specifically addresses the unapproved status of the compound, the absence of Phase III efficacy data, and the theoretical immunological concerns noted above.